title: Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions.
abstract: The efficacy and toxicity of donor leukocyte infusions (DLI) after unrelated donor bone marrow transplantation (BMT) is largely unknown. We identified 58 recipients of unrelated DLI (UDLI) for the treatment of relapsed disease from the National Marrow Donor Program database. A retrospective analysis was performed to determine response, toxicity, and survival after UDLI and to identify factors associated with successful therapy. UDLI was administered for relapsed chronic myelogenous leukemia (CML) (n = 25), acute myelogenous leukemia (AML) (n = 23), acute lymphoblastic leukemia (ALL) (n = 7), and other diseases (n = 3). Eight patients were in complete remission (CR) before UDLI, and 50 were evaluable for response. Forty-two percent (95% confidence interval [CI], 28%-56%) achieved CR, including 11 of 24 (46%; 95% CI, 26%-66%) with CML, 8 of 19 (42%; 95% CI, 20%-64%) with AML, and 2 of 4 (50%; 95% CI, 1%-99%) with ALL. The estimated probability of disease-free survival (DFS) at 1 year after CR was 65% (95% CI, 50%-79%) for CML, 23% (95% CI, 9%-38%) for AML, and 30% (95% CI, 6%-54%) for ALL. Acute graft-versus-host disease (GVHD) complicated UDLI in 37% of patients (grade II-IV, 25%). A total of 13 of 32 evaluable patients (41%) developed chronic GVHD. There was no association between cell dose administered and either response or toxicity. In a multivariable analysis, only a longer interval from BMT to relapse and BMT to UDLI was associated with improved survival and DFS, respectively. UDLI is an acceptable alternative to other treatment options for relapse after unrelated donor BMT. (Blood. 2000;95:1214-1221)
authors.affiliation: Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA. dlporter@mail.med.upenn.edu
authors.forename: D L
authors.initials: DL
authors.lastname: Porter
authors.forename: R H
authors.initials: RH
authors.lastname: Collins
authors.forename: C
authors.initials: C
authors.lastname: Hardy
authors.forename: N A
authors.initials: NA
authors.lastname: Kernan
authors.forename: W R
authors.initials: WR
authors.lastname: Drobyski
authors.forename: S
authors.initials: S
authors.lastname: Giralt
authors.forename: M E
authors.initials: ME
authors.lastname: Flowers
authors.forename: J
authors.initials: J
authors.lastname: Casper
authors.forename: A
authors.initials: A
authors.lastname: Leahey
authors.forename: P
authors.initials: P
authors.lastname: Parker
authors.forename: R
authors.initials: R
authors.lastname: Mick
authors.forename: B
authors.initials: B
authors.lastname: Bate-Boyle
authors.forename: R
authors.initials: R
authors.lastname: King
authors.forename: J H
authors.initials: JH
authors.lastname: Antin
mesh_terms: D000704:Analysis of Variance; D016026:Bone Marrow Transplantation; D016001:Confidence Intervals; D019992:Databases as Topic; D018572:Disease-Free Survival; D005260:Female; D006086:Graft vs Host Disease / Q000453:epidemiology; D006801:Humans; D007938:Leukemia / Q000401:mortality / Q000628:therapy*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy; D015470:Leukemia, Myeloid, Acute / Q000628:therapy; D017708:Leukocyte Transfusion; D019520:Living Donors; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000628:therapy; D012008:Recurrence; D012189:Retrospective Studies; D012307:Risk Factors; D016019:Survival Analysis; D016896:Treatment Outcome